CANMAb (Trastuzumab) for Injection (r-DNA Origin)
CANMAb is a brand-name prescription drug that’s FDA-approved to treat • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer). Brand Name: CANMAb (Trastuzumab) for Injection (r-DNA Origin).
Home | (Trastuzumab) for Injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Overseas Patient/ Export inquires.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
CANMAb (Trastuzumab) for Injection (r-DNA Origin)
Trastuzumab is approved to treat: • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer).
CANMAb is a HER2/neu receptor antagonist indicated for:
• the treatment of Metastatic Breast Cancer (MBC).
• the treatment of Early Breast Cancer (EBC).
• the treatment of EMetastatic Gastric Cancer (MGC).
A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, and Trazimera. Trastuzumab is approved to be used alone or with other drugs to treat: • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer)
Drug (Brand / Generic): CANMAb / Trastuzumab
Current Indications: • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma
Marketed by:: Biocon Biologics India Limited
Approval Date: 1998
Available as (Form & Strength): Reconstituted solutions made with bacteriostatic water for injection, as supplied, are stable (physico-chemically and 0 0 microbiologically) for 28 days, when refrigerated at 2 C to 8 C. The reconstituted solution is suitable for multiple uses, as it contains preservative. Discard any remaining reconstituted solution after 28 days. Do not freeze the reconstituted solution.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier / importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “CANMAb (Trastuzumab) for Injection”.
Confirmation of the order for ACANMAb (Trastuzumab) for Injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand CANMAb (Trastuzumab) for Injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to CANMAb (Trastuzumab) for Injection, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for CANMAb (Trastuzumab) for Injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.